Tumor-Infiltrating Lymphocytes (TILs): The Importance Of Starting Material In Breakthrough Cancer Treatments

TIL developers cannot choose the biology that enters the process, so the real question is where control begins. Maximizing cell yield is only part of it, since expansion also has to preserve the fitness and function of the cells being grown. Then come the weeks between tumor resection and infusion, when disease can progress and eligibility can shift. Research into process development, culture optimization, and cellular engineering points to more predictable expansion, but the source material still sets limits.

Find out which parts of the workflow developers can standardize and which they cannot. Read the article to see how expansion choices shape cell quality and the path to wider patient access.